PodcastIntel
Sign in Get Started Free
Citeline Podcasts
Citeline Podcasts

Scrip's Five Must-Know Things - Mar.16, 2026

Mar 16, 2026 · 14m
Listen to Episode
✨ AI Summary
  • Roche's giredestrant Phase III trial faced a setback.
  • BioNTech founders exited the company; Ipsen will withdraw Tazverik.
  • Bayer faces difficulties, while UCB's Bimzelx gains momentum.

More from Citeline Podcasts

Citeline Podcasts
Scrip's Five Must-Know Things - Oct. 13, 2026
Oct 13, 2026 · 16m
Citeline Podcasts
Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown
Oct 13, 2026 · 26m
Citeline Podcasts
Drug Fix: US FDA’s Peptide Drama, More Transparency, Ibogaine Clinical Trial Plans
Oct 9, 2026 · 41m
Citeline Podcasts
Off-Patent, On Record: Navigating The Financial Strategy Behind Litigation With Sandoz’s Julia Pike
Oct 6, 2026 · 24m
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to Citeline Podcasts and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →